Secukinumab Open Label Roll-over Extension Protocol

Inclusion Criteria:

1. Signed informed consent must be obtained for adult participants before anyassessment is performed. Written informed assent and parental permission (age as perlocal law) must be obtained for pediatric participants before any assessment isperformed. If participants reach age of consent (age as per local law) during thestudy, they will need to also sign the corresponding study informed consent(s).

2. Ability to communicate effectively with the investigator, to understand and willingto comply with the requirements of the study.

3. Participant has completed treatment per protocol in a Novartis study of secukinumab (unless otherwise specified in a parent study protocol). Participants, who derivebenefit from the treatment with secukinumab but have not completed the treatment incertain parent studies, due to parent study termination by Novartis, may be eligibleif the termination was due to reasons other than safety or lack of efficacy (technical / administrative reasons).

4. Participant is deriving benefit from secukinumab, investigator believes he/she wouldcontinue to derive benefit from secukinumab and the benefit outweighs the risk,based on the investigator's judgement.

5. Participant is unable to obtain access to the marketed secukinumab formulation perlocal prescription and/or reimbursement guidelines.

Exclusion Criteria:

1. Participant has prematurely discontinued study treatment in the parent protocol.

2. Women of childbearing potential, defined as all women physiologically capable ofbecoming pregnant, unless they are using methods of contraception during the entirestudy or longer if required by locally approved prescribing information (e.g., inEuropean Union (EU) 20 weeks).